18F-FluorThanatrace PET/CT for Pheochromocytoma and Paraganglioma
This study is looking at how a special imaging scan, called an 18F-FluorThanatrace (FTT) PET/CT, works in people with pheochromocytoma or paraganglioma. The scan uses a tracer, [18F]FTT, to show something called PARP-1 expression in your tumors. Researchers want to see if this scan can accurately measure PARP-1 in these tumors before you have surgery or other treatments. You would have this scan before your planned treatment. The study aims to enroll up to 30 adult patients who have been diagnosed with pheochromocytoma or paraganglioma and have at least one tumor visible on standard imaging.
- Study design
- This is an interventional study planning to enroll up to 30 participants. It is observational, meaning the scan results won't directly guide your treatment decisions.
- What's involved
- You would undergo an 18F-FluorThanatrace (FTT) PET/CT scan before surgery or systemic therapy. This involves an injection of [18F]FTT and approximately 60 minutes of dynamic scanning, followed by a second scan about 90 minutes later.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
At a glance
Conditions
NCT05636540
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvaniano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Heather Wachtel, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Standard uptake value (SUV)measurement - [F18]FTTBaseline
Qualitative measure SUV of \[18F\]FTT in phenochromocytoma/paraganlioma region (categories: positive, negative or mixed)
- Maximum standard uptake value (SUV)measurement - [F18]FTTBaseline
Measure of maximum SUV of \[18F}FTT in primary lesion region
- Mean Standard uptake value (SUV)measurement - [F18]FTTBaseline
Measure of mean SUV of \[18F}FTT in primary lesion region
- Peak Standard uptake value (SUV)measurement - [F18]FTTBaseline
Measure of peak SUV of \[18F}FTT in primary lesion region
- Standard uptake value (SUV)measurement - [F18]FTTFollow-Up (1-21 days post therapy)
Qualitative measure SUV of \[18F\]FTT in phenochromocytoma/paraganlioma region (categories: positive, negative or mixed)
- Maximum standard uptake value (SUV)measurement - [F18]FTTFollow-Up (1-21 days post therapy)
Measure of maximum SUV of \[18F}FTT in primary lesion region
- Mean Standard uptake value (SUV)measurement - [F18]FTTFollow-Up (1-21 days post therapy)
Measure of mean SUV of \[18F}FTT in primary lesion region
- Peak Standard uptake value (SUV)measurement - [F18]FTTFollow-Up (1-21 days post therapy)
Measure of peak SUV of \[18F}FTT in primary lesion region